Barclays raises Monopar Therapeutics price target to $145
Barclays raised its price target for Monopar Therapeutics to $145.00 per share from $128.00, keeping a maintained Overweight rating (via Benzinga).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.